Data-Sharing & Cost Disputes in REACH Consortia

REACH consortia bring together companies that may compete commercially but share regulatory obligations relating to the same substance – making collaboration both valuable and, at times, challenging.

Members may have different tonnage bands, different data requirements, different histories with the substance and different views on the scientific work required to maintain compliance. New registrants may also enter an established arrangement many years after the original studies were commissioned and paid for.

Against that background, disagreements are perhaps inevitable.

The objective of good consortium management isn’t to prevent every difference of opinion, but to create an environment in which questions can be raised and addressed fairly, transparently and constructively before they develop into significant obstacles.

Where Do REACH Consortium Disputes Typically Arise?

Cost is often the point at which a disagreement becomes visible, but the underlying issue may actually be scientific, regulatory or contractual.

Some of the most challenging discussions arise from questions such as:

• Are we really registering the same substance?
• Do we need this study?
• Why should my company contribute to this work?
• How has the price of accessing these data been calculated?
• Who should pay for new testing?
• What happens when a new registrant joins years later?

Understanding the underlying issue is the first step towards resolving it.

Substance Identity, Sameness & the Scope of Joint Registration

Before companies can share data effectively, there should be a common understanding of the substance being registered.

For relatively straightforward substances, this may present few difficulties. For more complex substances, however, differences in composition, constituents, impurities, manufacturing processes or substance identity profiles (SIP) can make the position considerably more complicated.

Questions may arise around whether:

• A potential registrant's substance falls within scope of an existing joint registration.
• Particular data are relevant across the substances represented within the group.
• Differences in composition affect the applicability of available studies.

A disagreement that initially appears to concern the cost of joining may therefore have a scientific issue at its heart.

Resolving it may require a review of substance identity information, composition ranges and the scope of the existing registration before any discussion of data access or cost can sensibly progress.

Which Studies Does a Registrant Actually Need?

Being part of the same joint submission does not necessarily mean that every registrant has identical information requirements.

Data requirements can differ according to factors such as tonnage band, registration status and registration type. A registrant may also already possess information relevant to a particular endpoint, subject to the applicable REACH requirements and the rules governing the use of existing data.

A member might therefore reasonably ask why it is being charged for a study it does not require.

Resolving this requires the available data package to be considered against that registrant's actual obligations. Clear itemisation should make it possible to identify:

• Which studies are included.
• Why each study is relevant.
• Which requirements it supports.
• What cost is attached to it.

This turns an apparently contentious total into something that can be reviewed on an endpoint-by-endpoint basis.

Disagreement Over the Scientific Approach

Sometimes companies agree that an endpoint needs to be addressed but disagree over how this should be achieved.

• Should the consortium commission a new study?
• Could an existing study be sufficient?
• Might read-across, a weight-of-evidence approach, QSAR or another scientifically justified alternative meet the requirement?

These are scientific and regulatory questions, but they also have financial consequences.

Commissioning additional testing may represent a significant investment, while choosing an alternative approach requires confidence that it is scientifically robust and appropriate for the regulatory purpose.

In these situations, the solution is not simply to negotiate the price. The consortium first needs an agreed scientific and regulatory rationale for the proposed approach. Only then can members make an informed decision about the associated expenditure.

The cheapest approach is not necessarily the right one, but neither should members incur unnecessary costs without clear justification.

How Should Existing Studies Be Valued?

Historical studies present another potential source of disagreement.

A study may have been commissioned many years earlier by one company or a small group of original registrants. A new participant subsequently seeking access may question how its value has been determined.

Considerations may include:

• The documented cost of generating or acquiring the study.
• The basis on which that cost has been allocated.
• The relevance of the study to the registrant's information requirements.
• The age and quality of the information.
• Previous contributions made by other registrants.
• The applicable cost-sharing and reimbursement methodology.

There is also an important distinction where studies were submitted for registration more than 12 years ago. Under REACH, a potential registrant does not have to pay for access to a study that was submitted more than 12 years previously where the study is being used for the purpose of registration. This can be particularly relevant when assessing the value of historical data and determining which costs should properly form part of a new registrant's data-sharing contribution.

The important issue is not simply which valuation methodology is used, but whether the resulting cost allocation can be explained, supported and applied consistently in accordance with the applicable REACH requirements.

Where a value is challenged, the consortium should be able to reconstruct the basis for the calculation and provide a clear rationale rather than relying on a historic figure that can no longer be substantiated.

Letter of Access Costs & What They Include

The price of a Letter of Access can become particularly contentious when a new or potential registrant does not understand what it is being asked to pay for.

Questions may arise around:

• Which studies are included.
• Whether all those studies are required by that registrant.
• How study values have been calculated.
• Which administrative costs have been added.
• Whether Chemical Safety Report preparation is included and if that information is actually required by the registrant.
• How the cost-sharing methodology has been applied.

The distinction between data costs and administrative costs is particularly important.

When a Letter of Access price is challenged, one of the most effective responses is to break the total down into its component parts and explain the basis for each element.

Clear itemisation allows both parties to discuss the actual issue rather than negotiating around a single unexplained figure.

New Studies & Additional Regulatory Requirements

REACH registrations continue to evolve after initial submission.

New information requirements, dossier evaluation, changes in scientific understanding or other regulatory developments can create a need for additional work.

This can trigger difficult questions:

• Is the proposed work genuinely necessary?
• Which registrants require the resulting information?
• Who should contribute?
• How should the cost be divided?
• When should payment be requested?

These questions become particularly sensitive where the anticipated work is expensive or relevant only to part of the consortium.

The practical solution is to separate two decisions.

First: establish whether the work is scientifically justified and required under the applicable REACH information requirements.

Second: determine which members require or will use the resulting information and then apply the agreed and applicable cost-sharing methodology.

Keeping those questions separate can prevent a debate about cost from obscuring the underlying regulatory need.

New Registrants, Historical Costs & Reimbursement

An established consortium may have funded significant work long before a new registrant enters the market.

A new registrant seeking access to existing data may be required to make an appropriate contribution under the applicable data-sharing arrangement. Where additional registrants subsequently contribute to the costs of jointly used data, the applicable cost-sharing and reimbursement mechanisms may require contributions to be recalculated, and previous contributors reimbursed where appropriate.

This is why clear reimbursement mechanisms are an important part of a REACH data-sharing agreement. Without a clear mechanism, both sides can feel disadvantaged; new registrants may perceive an excessive barrier to entry, while longstanding members may believe newcomers are benefiting disproportionately from investments they originally funded.

A transparent reimbursement model established before the issue arises makes these discussions considerably easier to manage.

Administrative Costs Can Be Contentious Too

Not every dispute concerns scientific studies.

Consortium management itself creates legitimate expenditure, including administration, financial management, dossier coordination, legal support, communications and management of access to the joint submission.

Disagreement tends to arise when these charges are bundled together or insufficiently explained.

The key questions are:

• What activity does this cost relate to?
• Who benefits from it?
• And how has it been allocated?

Good records and clear cost categories make those questions much easier to answer.

Intellectual Property & Data Ownership

Complexity can also arise where the consortium does not own all the information within the registration.

Studies may belong to individual member companies, third parties or other groups. Their use may be governed by contractual arrangements, ownership rights or restrictions on further access.

Before offering access to data, the consortium therefore needs to understand not only what information exists, but what rights it actually has to use, share or license it.

This can become particularly important when new registrants seek access to an established dossier.

Preventing Differences Becoming Disputes

Many of these situations involve legitimate questions rather than unreasonable behaviour by either party.

Problems tend to escalate when those questions cannot be answered clearly.

Five principles are particularly important:

Understand the Actual Concern

A question about study relevance requires a scientific answer. A question about valuation requires a financial explanation. A question about data ownership may require contractual review.

Treating every challenge simply as resistance to paying can make resolution considerably harder.

Explain the Methodology

Members and prospective registrants should be able to understand how costs, valuations and contributions have been determined.

Keep Detailed Records

Study valuations, cost calculations, decisions, approvals and correspondence should be documented so that the history behind an arrangement can be reconstructed.

Apply Principles Consistently

Comparable participants should be treated according to the same established methodology.

Address Concerns Early

Questions are generally easier to resolve while they remain questions. Allowing uncertainty or frustration to accumulate can unnecessarily entrench positions.

What Happens When Agreement Cannot Be Reached?

Under EU REACH, registrants are expected to make every effort to reach agreement on sharing information and its costs.

EU REACH provides formal mechanisms for certain data-sharing disputes where registrants have been unable to reach agreement despite making every effort to reach agreement.

Good records become particularly important at this stage. The history of negotiations, information exchanged, explanations provided and efforts made to reach agreement may all become significant.

Where possible, resolving the underlying issue through constructive discussion remains preferable for organisations that may need to continue working together for many years.

The Value of Independent Consortium Management

Independence can be particularly valuable when discussions become sensitive.

An experienced consortium manager occupies a different position from an individual member company. Rather than advocating for one commercial interest, the manager can help ensure that agreed processes are followed consistently and that discussions remain grounded in the regulatory, scientific and financial facts.

This may involve:

• Coordinating data-sharing negotiations.
• Explaining cost and reimbursement methodologies.
• Maintaining study and financial records.
• Facilitating scientific discussions around data requirements.
• Managing Letters of Access and new registrant requests.
• Coordinating communications between members.
• Documenting decisions and agreements.
• Identifying issues before they escalate.

Good dispute management therefore isn’t simply about mediating after relationships have deteriorated. Much of its value comes from establishing the scientific, financial and administrative structures that allow questions to be answered before they become disputes.

Good Consortium Management Protects Long-Term Collaboration

A REACH consortium may exist for many years, during which its membership, regulatory obligations and data requirements can all change.

Successful consortium management does not mean that every member will always agree. It means creating a framework in which disagreements can be understood, evaluated and resolved fairly, while allowing the consortium to continue meeting its regulatory responsibilities.

Blue Frog Supports REACH Consortia

Blue Frog provides independent consortium management services covering the regulatory, scientific, administrative and financial requirements of long-term chemical collaborations.

Our multidisciplinary team can support data-sharing and cost negotiations, Letters of Access, study and data management, financial administration, member communications and the resolution of complex consortium issues.

By combining regulatory and scientific understanding with experienced consortium management, we help clients address not just the financial question, but the underlying technical and regulatory issues that can give rise to it.

If you need support managing an existing REACH consortium, responding to a data-sharing challenge or establishing robust processes for future collaboration, contact Blue Frog and speak directly with one of our REACH consortium management experts.